The XPNPEP2 antibody is a tool used to detect X-prolyl aminopeptidase 2 (XPNPEP2), a membrane-bound metalloprotease involved in cleaving N-terminal amino acids from peptides containing proline or alanine residues. XPNPEP2. also known as aminopeptidase P2. plays a role in metabolizing bioactive peptides, including bradykinin and collagen-derived fragments. It is expressed in various tissues, particularly the kidneys, liver, and intestines. Research has linked XPNPEP2 to genetic and pathological conditions, such as autosomal recessive kidney disease caused by mutations in the XPNPEP2 gene, which disrupts ciliary function in renal tubular cells. Additionally, XPNPEP2 deficiency has been associated with reduced enzymatic activity of aminopeptidase P, potentially contributing to angioedema in patients taking ACE inhibitors due to impaired bradykinin degradation. Antibodies targeting XPNPEP2 are primarily utilized in biomedical research to study its expression, localization, and function in cellular and disease models. They are commonly applied in techniques like Western blotting, immunohistochemistry, and immunofluorescence to analyze protein levels in tissue samples or cultured cells. These antibodies aid in elucidating XPNPEP2's role in ciliopathies, metabolic disorders, and drug-related side effects, providing insights into therapeutic targeting and diagnostic biomarker development. Validation of antibody specificity often involves knockout controls or enzymatic activity assays.